How to Invest in CRISPR Therapeutics Stock

How to buy CRISPR stock

It's easy to invest in CRISPR Therapeutics since it's a publicly traded company. Follow the steps below to buy CRISPR stock.

1. Open your brokerage account: Log in to your brokerage account where you handle your investments.
2. Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
3. Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
4. Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
5. Submit your order: Confirm the details and submit your buy order.
6. Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

Should I invest in CRISPR stock?

With CRISPR Therapeutics, it's all about potential. By investing in it, you could get in early with a company that could explode in value, depending on how its product development goes.

Along with partner Vertex Pharmaceuticals (VRTX +0.15%), CRISPR Therapeutics submitted its first treatment, Casgevy (exa-cel), for approval by regulators in 2023. The U.S. Food and Drug Administration approved Casgevy for treatment of sickle cell disease in December 2023 and for treatment of beta-thalassemia in January 2024. And as of June 30, 2025, the company announced that more than 75 authorized treatment centers had been activated globally.

CRISPR Therapeutics receives 40% of profits on Casgevy. The treatment brought in $44.6 million in revenue in the first half of 2025.

The advancement of Casgevy is good news for investors. CRISPR Therapeutics also has other treatments it's developing. It has several cancer therapies in the early-to-mid stages, and it has three clinical-stage programs that would use gene editing to treat cardiovascular disease.

It's important not to be overly optimistic. Biotech is one of the riskiest market sectors, so this is a stock for more aggressive investors. That being said, there's a lot to like about CRISPR stock as an investment. Just remember to be patient and plan to hold it for at least five years.

Is CRISPR Therapeutics profitable?

CRISPR Therapeutics isn't profitable. It reported a net loss of $362.7 million in 2024. The company also states in its annual report that it has incurred significant operating losses since its inception and expects to do so for the foreseeable future.

This is normal for biotech companies, which are generally unprofitable for long periods of time while developing treatments. It's one of the main reasons they're a higher-risk investment.

Does CRISPR Therapeutics pay a dividend?

CRISPR Therapeutics doesn't pay a dividend and is unlikely to in the foreseeable future. Biotech stocks rarely pay dividends, since it makes more sense for them to reinvest profits in developing new treatments. People interested in dividend investing don't have many options in this space.

The bottom line on CRISPR Therapeutics

Gene editing is looking like a major innovation for the healthcare industry, and CRISPR Therapeutics is at the forefront. All of its product candidates use the CRISPR gene-editing technique. With one approved product so far and more hopefully on the way, the sky's the limit.

There are a couple of things to keep in mind if you want to invest in CRISPR stock. The risk and reward are both higher with biotech companies than with most market sectors. You also shouldn't expect immediate results with CRISPR Therapeutics, since most of its treatments are still in the early stages. This is a stock for patient investors who are comfortable with volatility.

FAQs